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Purpose of review: The recent advances in the use of targeted therapy in pancreatic 
cancer are based on the knowledge of genetic alterations that occur during 
pancreatic carcinogenesis. We describe the repository of frequent alterations 
targeting tumor suppressor genes and oncogenes. We focus our attention on the 
EGFR signaling pathway, which can be activated through different alterations and 
seems to play a central role in the cell transformation. Multiple targeted drugs have 
been developed against different partners of this network trying to improve the 
treatment of pancreatic cancer patients. Recent findings: Tarceva has obtained 
approval in the USA and Europe for metastatic pancreatic cancer with a modest 
increase of median survival and a 6% increase in one-year survival rates, suggesting 
that only a small fraction of patients truly benefit of it. The comparison with lung and 
colon cancer suggests that KRAS mutations could be a predictive marker of 
resistance. Other promising drugs targeting different partner of the EGFR signalling 
pathway could play a synergistic role with tarceva as inhibitors of mTOR, MEK, and 
NFKB or can directly turn down RAS. Summary: The biology of EGFR, MAPK, 
PI3K/mTOR network suggests that combination of drugs targeting simultaneously 
different partners should improve survival. 
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Introduction 
 
As cancer is caused by alteration in oncogenes, tumor suppressor genes and 
microRNA [1], the  knowledge of the these alterations should be of help to understand 
the mechanisms of cell transformation and also to find appropriate targeted anti-
cancer treatments. Among human solid tumors, pancreatic cancer is one of the most 
studied for the genetic alterations that occurs during cell transformations. Incidence 
and mortality rate (between 5 and 11 to 100000 inhabitants) are close underlying the 
extreme severity of this disease. Until a recent time, the only treatment with an 
impact on survival was surgery. In the palliative setting gemcitabine remains since 
1997 the standard treatment despite poor response rate and survivals. The recent 
introduction of targeted therapies in the therapeutic armamentarium against cancer 
raised some hopes in the treatment of patients with advanced or metastatic diseases. 
The knowledge of the molecular events occurring in the malignant transformation 
processes should allow the development of efficient targeted therapies.  
 
Chromosomal instability in pancreatic cancer 
 
This tumour is not only homogeneous in its clinical presentation, but also in its 
histological characteristics. Although biliary epithelium represents less than 5 % of 
the whole pancreatic cells, more than 90% of pancreatic cancers are 
adenocarcinoma coming form the malignant transformation of this epithelium. The 
particular aggressiveness of these tumours is owing to the existence of an important 
genetic plasticity of the pancreatic tumour cells. Indeed this tumour is probably one of 
the human solid tumour for which genetic alterations are found with highest 
prevalence. The mean number of chromosomal arm lost in pancreatic tumour cells is 
14 out of the 39 autosomal segments. In more than 60% of pancreatic cancer one of 
the following chromosome arms are lost 1p, 9p, 17p and 18q. Allelic losses on 3p, 
6p, 6q, 8p, 10q, 12q, 13q, 18p, 21q and 22q are observed in 30 to 60 % of the cases. 
Associated with these losses, gains of chromosome arms are found in 16p, 20p, 17p 
and recurrent amplified regions are found in 6q24, 7q22, 12p13 [2].  
Allelic losses take part in the inactivation of tumor suppressors genes. In the most 
frequent chromosomal arm lost, the second copy of the tumor suppressor gene was 
found inactivated in 75% of the cases. In the 9p the allelic loss target is p16 gene, 
which codes a protein that inhibits the complex Cyclin D-CdK4 and Cyclin D-cdk6 key 
players of cell cycle. In pancreatic adenocarcinoma p16 is inactivated in more than 
90% of the cases. This bi-allelic inactivation is owing to homozygous deletion or by 
the association of allelic losses and inactivating point mutation or by 
hypermethylation of the enhancer region of the gene. In 17p the gene targeted by the 
deletion is TP53 and the prevalence of point mutation of this gene is up to 70% in 
adenocarcinoma of the pancreas. In chromosome 18q arm the characterization of 
homozygous deletion had allowed the identification of a tumour suppressor gene 
initially named DPC4 for deleted in pancreatic cancer. This gene had been renamed 
MADH4 (Mother Against Decapentaplegic Homolog) it codes for a protein that 
participates to the transduction of TGFß signaling pathway. This gene is inactivated 
in 35% of the cases by homozygous deletions or by the association of allelic loss and 
inactivating mutation in 20% of the cases [3]. 
The tumor suppressor gene targeted by allelic loss occurring in the 1p has not been 
yet identified; a most recent hypothesis suggests that the gene targeted could be a 
microRNA.  
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EGFR signalling pathways 
 
Others alterations lead to the activation of oncogenes. Among them, KRAS 
mutations in pancreatic cancer occur in more than 70% of the cases (Cosmic 
database, http://www.sanger.ac.uk/genetics/CGP/cosmic). These mutations occur in 
the first two nucleotides of codon 12, more rarely in codon 13 or 61 resulting in the 
constitutive activation of the MAPK and PI3K/AKT signal transduction pathways. 
Among other oncogenes implicated in pancreatic cancer a special mention must be 
made for the EGF receptor family. Oncogene HER2, overexpression in pancreatic 
cancer, has been reported to vary widely from 10 to 82% [4-6], as HER1 is commonly 
expressed in pancreatic cancer.  
This activation of EGF pathway leads to a cascade of phosphorylation in the 
Ras, PI(3)K (phosphatidylinositol-3-OH kinase) and mTOR (mammalian target of 
rapamycin) signalling pathways which forms an intersecting biochemical network 
that, when mutated, drives cell growth in a manner unrestricted by environmental 
cues. Ultimately, these pathways drive tumorigenesis through the coordinated 
phosphorylation of proteins that directly regulate protein synthesis, cell-cycle 
progression and metabolism, and of transcription factors that regulate the expression 
of genes involved in these processes affecting cellular proliferation, angiogenesis, 
apoptosis, and metastatic spread [7]. Therefore the mTOR protein kinase has 
emerged as a critical growth control node, receiving stimulatory signals from Ras and 
PI(3)K downstream from growth factors, as well as nutrient inputs in the form of 
amino-acid, glucose and oxygen availability. Notably, components of the Ras and 
PI(3)K signalling pathways are mutated in most human cancers. The preponderance 
of mutations in these interconnected pathways suggests that the loss of growth-
control checkpoints and promotion of cell survival in nutrient limited conditions may 
be an obligate event in tumorigenesis. Furthermore, since most of the recently 
clinically approved or developing targeted anticancer agents focused on partners of 
these signalling pathways, understanding the full circuitry of Ras, PI(3)K and mTOR 
signalling pathways, including feedback loops, is a requirement for an understanding 
of the biological consequences of perturbing that pathway by targeted anticancer 
agents as inhibitors of mTOR or other PI(3)K signalling components. Defining the 
combinations of inhibitors that are likely to be effective on tumors with specific 
combinations of genetic lesions will be an even greater challenge. However, on the 
basis of our increasing understanding of these networks, there is great hope that this 
strategy will ultimately be highly effective. As more drugs that target specific 
components of signal transduction pathways become available and as we increase 
our knowledge of the complexity of these signalling networks, the burden of selecting 
the correct drug combinations for each individual cancer patient will ultimately shift to 
the pathologist, who must identify the underlying defect in each tumor. This will 
require new diagnostic technologies and will be a major challenge over the next 
decade. 
 
KRAS mutations 
 
From the description of the repository of genetic alterations occurring in 
pancreatic cancer the alteration of EGFR pathway appears central either by the 
expression of the receptor itself or by the occurrence of KRAS mutation. Two classes 
of epidermal growth factor receptor (EGFR) inhibitors (antibodies ie antiEGFR or 
small molecules ie EGFR-TKI) have been tested in human cancers and from the 
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experience from 2 others tumor locations we could have predicted the absence or the 
weak effectiveness of these treatments in pancreatic cancer patients. Indeed, in 
colorectal cancer, it has been now clearly shown that KRAS mutations were 
associated with resistance to antiEGFR (cetuximab and panitumumab) in patients 
with metastatic disease and that KRAS wild-type state predicts the efficacy of these 
treatments in terms of morphological objective response and survival [8-11]. In non 
small cell lung cancer KRAS mutation is an important predictor of poor response and 
outcome to EGFR-TKIs (erlotinib and gefitinib) [12]. In pancreatic cancer the addition 
of cetuximab to gemcitabine has not shown any benefit [13] whereas the addition of 
erlotinib, another EGFR inhibitor, to gemcitabine has given positive results with a 
statistically significant improvement in overall survival [14]. This drug has obtained 
approval in the USA and Europe. However the median survival increased in the 
experimental arm only of 10 days and difference between survival rate at 1 year 
increased from 17% to 23% leading to suggest a true benefit for only 6% of the 
patient. This study raises the issue of the status of KRAS for the patients that benefit 
from the treatment by erlotinib. The cost benefit of such treatment is largely 
dependant to the answer of this question.  
 
HER 2 inhibitors  
 
Concerning the approach of inhibiting HER2, the results are controversial and 
once again the absence of a well defined tumour population has probably impaired 
the results of the only phase II using trastuzumab a recombinant humanized IgG1 
monoclonal antibody against HER2 in pancreatic cancer. There is evidence for 
positive in vitro and in vivo results in pancreatic cancer cell lines and in xenograft 
tumour models in a subgroup of tumour with high level HER2 protein (3+) treated by 
trastuzumab [15].  However the only phase II using a combination of gemcitabine plus 
trastuzumab is negative showing only 6% response (2 of 32 cases) which is not 
superior to therapy with gemcitabine alone [16]. One of the explanations of this 
negative result could be that 90% (30 of 34 patients) of enrolled patients in the trial 
showed only a moderate (2+) expression of HER2, which is not the highest grade of 
expression. The true clinical advantage of trastuzumab in patients with high 
expression (3+) of HER2 therefore remains unclear.  
 
 
MEK-1 and mTOR inhibitors  
 
New drugs targeting several proteins downstream from EGF receptor are in 
various stages of clinical development. In particular a selective small-molecule 
inhibitor (CI-1040) of the dual-specificity kinases MEK (mitogen-activated protein 
kinase kinase) -1 and MEK-2 that is orally active has shown both target suppression 
and antitumour activity in a phase I study [17]. One partial response out of six patients 
with pancreatic cancer enrolled in this trial, has been observed. Furthermore the dual 
targeting of the EGFR and MAPK pathway by tarceva and CI-1040 is associated with 
antitumor effects in four different pancreatic cancer xenografts with up-regulation and 
activation of both pathways that are resistant to each intervention separately, 
suggesting a synergistic effects of this combined therapeutic modality [18]. These 
results provide the basis to test EGFR inhibitors in combination with inhibitors of the 
MAPK in phase I and phase II trials for pancreatic cancer patients. 
Furthermore as the Ras–MAPK and PI(3)K pathways are strongly interconnected, 
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disruption of one will, in many cases, push tumour cells to increase flux through the 
other in a virtual tug of war between proliferation and survival signals. One potential 
strategy to overcome this problem is to combine drugs against several relevant 
targets. For example combined inhibition of EGFR and PI(3)K signalling in 
phosphatase and tensin homologue (PTEN)-mutated tumours has been shown to be 
a rational and therapeutically advantageous approach [19]. In this context there is 
some evidence that inhibitor of mTor (Mammalian Target of rapamycin) could be 
efficient in pancreatic cancer treatment. It has been shown that the signalling 
pathways regulating mTOR are frequently activated in pancreatic cancer, and that a 
rapamycin derivative (CCI-779; temsirolimus) could inhibit tumour growth in xenograft 
models as a single agent as well as combined with gemcitabine [20]. A least 2 ongoing 
trials are currently testing this agent in locally advanced or metastatic pancreatic 
cancer patients alone or in combination with gemcitabine (NCT00075647 ; 
NCT00593008).  
 
 
NF-kB inhibitors 
 
The PI3K mTor activation signalling pathways lead at the end to the activation of the 
ubiquitous transcription factor, nuclear factor kappa B (NF-kappaB) (for schematic 
representation see http://www.genome.ad.jp/kegg/pathway/hsa/hsa05212.html). NF-κB 
activation is important to pancreatic cancer growth and metastases. A large number 
of compounds are currently known as NF-kappaB modulators and include the 
isoprenoids, most notably kaurene diterpenoids and members of the sesquiterpene 
lactones class, several phenolics including curcumin and flavonoids such as silybin 
[21]. It has been shown in human pancreatic cancer cell lines that curcumin 
(diferuloylmethane) can suppress NF-κB, COX-2, PGE-2, IL-8 expression and cell 
proliferation in pancreatic malignancies, and all of these curcumin-induced changes 
are associated with potent proapoptotic effects suggesting a potential anti-tumoral 
effect in pancreatic cancer patients [22]. Furthermore Curcumin increased the 
inhibitory effect of gemcitabine on cell viability as well as its pro-apoptotic effect in 
COX-2 positive pancreatic cancer cell line [23]. After the proof of concept, three 
clinical trials testing curcumin (NCT00192842 ; NCT00094445 ; NCT00486460) in 
association with gemcitabine or celebrex are currently ongoing. 
 
Antisense Therapy  
 
Another therapeutic approach to target downstream effectors of the EGFR pathways 
is the antisense therapy. Antisense oligonucleotides are designed as a 
complimentary sequence of base pairs to a specific mRNA that in turn permits the 
sequence to bind to the mRNA and therefore block its expression. Different antisense 
oligonucleotides have been used targeting KRAS or HRAS in pancreatic cancer cell 
lines with promising results. ISIS-2503 is a phosphorothioate oligonucleotide 
antisense inhibitor of human H-ras mRNA expression which has shown significant 
antitumor activity against a variety of human tumors implanted in athymic nude mice, 
including two pancreatic carcinoma cell lines. Furthermore in a phase II study the 
combination of gemcitabine and ISIS-2503 demonstrated activity in patients with 
pancreatic adenocarcinoma. In a patient population in which 90% of the patients had 
metastatic disease, a median overall survival of 6.7 months and an objective 
response rate of 10%, including one complete response were observed suggesting a 
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potential positive effect of this drug [24]. 
 
Conclusion 
 
 Considerable excitement has arisen over the past years with the 
development and approval of a number of new therapeutic agents that have 
increased options and significantly improved outcomes of patients with cancer. 
However, recent randomized trials in pancreatic cancer gave poor results. It is 
becoming increasingly apparent that the complexity of the EGFR signalling cascade 
provides a wealth of mechanisms for resistance to EGFR targeted agents in patients 
with pancreatic cancer. Combination therapy with targeted agents should be efficient 
in these patients. Moreover, in order to select the best combination of targeted 
therapies we need to develop tools for the physician in order to identify the best 
treatment for a given patient and allowing the treatment “à la carte”. The extensive 
characterization of genetic alterations of signalling pathways appeared to be a 
promising way in order to identify predictive factors of response to targeted therapies. 
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